LEDAGA® (chlormethine) gel is an alkylating drug indicated for the topical treatment of MF-CTCL in adult patients. LEDAGA® is a gel which is applied topically once a day. The drug has been approved by the European Commission (for the treatment of MF-CTCL in adult patients). Since June 2019, LEDAGA® is commercialized in more than 30 countries including Europe, Canada, Latin America.*
TRUSELTIQ® (infigratinib) capsules 25mg/100mg is indicated for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. TRUSELTIQ® is a pipeline therapy which has already been approved for 2nd Line with Phase 3 Trials and is currently under investigation as a potential first-line treatment for individuals with Adjuvant Urothelial Cancer in Australia.*
*The exact therapeutic indication and registration status may be different in each country. Please consult the official approved product information in your country.